Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Turning the corner on therapeutic cancer vaccines.

Hollingsworth RE, Jansen K.

NPJ Vaccines. 2019 Feb 8;4:7. doi: 10.1038/s41541-019-0103-y. eCollection 2019. Review.

2.

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.

Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, Bannister D, Jovanovic J, Fleming R, D'Hooge F, Mao S, Marrero AM, Korade M 3rd, Strout P, Xu L, Chen C, Wetzel L, Breen S, van Vlerken-Ysla L, Jalla S, Rebelatto M, Zhong H, Hurt EM, Hinrichs MJ, Huang K, Howard PW, Tice DA, Hollingsworth RE, Herbst R, Kamal A.

Mol Cancer Ther. 2017 Aug;16(8):1576-1587. doi: 10.1158/1535-7163.MCT-16-0825. Epub 2017 May 18.

3.

5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma.

Kerk SA, Finkel KA, Pearson AT, Warner KA, Zhang Z, Nör F, Wagner VP, Vargas PA, Wicha MS, Hurt EM, Hollingsworth RE, Tice DA, Nör JE.

Clin Cancer Res. 2017 May 15;23(10):2516-2527. doi: 10.1158/1078-0432.CCR-16-1834. Epub 2016 Oct 25.

4.

Targeting CD73 in the tumor microenvironment with MEDI9447.

Hay CM, Sult E, Huang Q, Mulgrew K, Fuhrmann SR, McGlinchey KA, Hammond SA, Rothstein R, Rios-Doria J, Poon E, Holoweckyj N, Durham NM, Leow CC, Diedrich G, Damschroder M, Herbst R, Hollingsworth RE, Sachsenmeier KF.

Oncoimmunology. 2016 Jul 11;5(8):e1208875. doi: 10.1080/2162402X.2016.1208875. eCollection 2016 Aug.

5.

Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies.

Zhong H, Fazenbaker C, Chen C, Breen S, Huang J, Yao X, Ren P, Yao Y, Herbst R, Hollingsworth RE.

Oncogene. 2017 Feb 9;36(6):797-806. doi: 10.1038/onc.2016.248. Epub 2016 Jul 11.

PMID:
27399333
6.

Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.

Thompson P, Fleming R, Bezabeh B, Huang F, Mao S, Chen C, Harper J, Zhong H, Gao X, Yu XQ, Hinrichs MJ, Reed M, Kamal A, Strout P, Cho S, Woods R, Hollingsworth RE, Dixit R, Wu H, Gao C, Dimasi N.

J Control Release. 2016 Aug 28;236:100-16. doi: 10.1016/j.jconrel.2016.06.025. Epub 2016 Jun 18.

PMID:
27327768
7.

Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant Setting.

Hu Y, Lu L, Xia Y, Chen X, Chang AE, Hollingsworth RE, Hurt E, Owen J, Moyer JS, Prince ME, Dai F, Bao Y, Wang Y, Whitfield J, Xia JC, Huang S, Wicha MS, Li Q.

Cancer Res. 2016 Aug 15;76(16):4661-72. doi: 10.1158/0008-5472.CAN-15-2664. Epub 2016 Jun 20.

8.

IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence.

Finkel KA, Warner KA, Kerk S, Bradford CR, McLean SA, Prince ME, Zhong H, Hurt EM, Hollingsworth RE, Wicha MS, Tice DA, Nör JE.

Neoplasia. 2016 May;18(5):273-281. doi: 10.1016/j.neo.2016.03.004. Epub 2016 Apr 15.

9.

A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.

Xiao Z, Carrasco RA, Schifferli K, Kinneer K, Tammali R, Chen H, Rothstein R, Wetzel L, Yang C, Chowdhury P, Tsui P, Steiner P, Jallal B, Herbst R, Hollingsworth RE, Tice DA.

Mol Cancer Ther. 2016 Apr;15(4):689-701. doi: 10.1158/1535-7163.MCT-15-0555. Epub 2016 Feb 15.

10.

A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.

Zhong H, Davis A, Ouzounova M, Carrasco RA, Chen C, Breen S, Chang YS, Huang J, Liu Z, Yao Y, Hurt E, Moisan J, Fung M, Tice DA, Clouthier SG, Xiao Z, Wicha MS, Korkaya H, Hollingsworth RE.

Cancer Res. 2016 Jan 15;76(2):480-90. doi: 10.1158/0008-5472.CAN-15-0883. Epub 2016 Jan 7.

11.

HER2 drives Mucin-like 1 to control proliferation in breast cancer cells.

Conley SJ, Bosco EE, Tice DA, Hollingsworth RE, Herbst R, Xiao Z.

Oncogene. 2016 Aug 11;35(32):4225-34. doi: 10.1038/onc.2015.487. Epub 2016 Jan 4.

12.

Interleukin-6 Stimulates Defective Angiogenesis.

Gopinathan G, Milagre C, Pearce OM, Reynolds LE, Hodivala-Dilke K, Leinster DA, Zhong H, Hollingsworth RE, Thompson R, Whiteford JR, Balkwill F.

Cancer Res. 2015 Aug 1;75(15):3098-107. doi: 10.1158/0008-5472.CAN-15-1227. Epub 2015 Jun 16.

13.

A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways.

Rios-Doria J, Sabol D, Chesebrough J, Stewart D, Xu L, Tammali R, Cheng L, Du Q, Schifferli K, Rothstein R, Leow CC, Heidbrink-Thompson J, Jin X, Gao C, Friedman J, Wilkinson B, Damschroder M, Pierce AJ, Hollingsworth RE, Tice DA, Michelotti EF.

Mol Cancer Ther. 2015 Jul;14(7):1637-49. doi: 10.1158/1535-7163.MCT-14-1040. Epub 2015 May 6.

14.

Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer.

Milagre CS, Gopinathan G, Everitt G, Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R, Bowtell DD, Hochhauser D, Balkwill FR.

Cancer Res. 2015 Apr 1;75(7):1255-64. doi: 10.1158/0008-5472.CAN-14-1801. Epub 2015 Feb 10.

15.

Cancer stem cell plasticity and tumor hierarchy.

Cabrera MC, Hollingsworth RE, Hurt EM.

World J Stem Cells. 2015 Jan 26;7(1):27-36. doi: 10.4252/wjsc.v7.i1.27. Review.

16.

MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas.

Zhong H, Fazenbaker C, Breen S, Chen C, Huang J, Morehouse C, Yao Y, Hollingsworth RE.

Mol Cancer Ther. 2014 Nov;13(11):2662-73. doi: 10.1158/1535-7163.MCT-14-0144. Epub 2014 Sep 5. Erratum in: Mol Cancer Ther. 2015 Mar;14(3):844.

17.

A New Bliss Independence Model to Analyze Drug Combination Data.

Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth RE, Yang H.

J Biomol Screen. 2014 Jun;19(5):817-21. doi: 10.1177/1087057114521867. Epub 2014 Feb 3.

PMID:
24492921
18.

Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling.

Michaud NR, Wang Y, McEachern KA, Jordan JJ, Mazzola AM, Hernandez A, Jalla S, Chesebrough JW, Hynes MJ, Belmonte MA, Wang L, Kang JS, Jovanovic J, Laing N, Jenkins DW, Hurt E, Liang M, Frantz C, Hollingsworth RE, Simeone DM, Blakey DC, Bedian V.

Mol Cancer Ther. 2014 Feb;13(2):386-98. doi: 10.1158/1535-7163.MCT-13-0420. Epub 2013 Dec 16.

19.

Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.

Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJ.

Clin Cancer Res. 2013 Jun 1;19(11):2984-94. doi: 10.1158/1078-0432.CCR-12-2008. Epub 2013 Apr 2.

20.

EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter.

van Vlerken LE, Kiefer CM, Morehouse C, Li Y, Groves C, Wilson SD, Yao Y, Hollingsworth RE, Hurt EM.

Stem Cells Transl Med. 2013 Jan;2(1):43-52. doi: 10.5966/sctm.2012-0036. Epub 2012 Dec 27.

21.

Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment.

Laurent-Matha V, Huesgen PF, Masson O, Derocq D, Prébois C, Gary-Bobo M, Lecaille F, Rebière B, Meurice G, Oréar C, Hollingsworth RE, Abrahamson M, Lalmanach G, Overall CM, Liaudet-Coopman E.

FASEB J. 2012 Dec;26(12):5172-81. doi: 10.1096/fj.12-205229. Epub 2012 Aug 16.

22.

The role of epigenetic regulation in stem cell and cancer biology.

van Vlerken LE, Hurt EM, Hollingsworth RE.

J Mol Med (Berl). 2012 Jul;90(7):791-801. doi: 10.1007/s00109-012-0917-9. Epub 2012 Jun 2. Review.

PMID:
22660276
23.

Spiral plasmonic nanoantennas as circular polarization transmission filters.

Bachman KA, Peltzer JJ, Flammer PD, Furtak TE, Collins RT, Hollingsworth RE.

Opt Express. 2012 Jan 16;20(2):1308-19. doi: 10.1364/OE.20.001308.

PMID:
22274476
24.

Ultra-high extinction ratio micropolarizers using plasmonic lenses.

Peltzer JJ, Flammer PD, Furtak TE, Collins RT, Hollingsworth RE.

Opt Express. 2011 Sep 12;19(19):18072-9. doi: 10.1364/OE.19.018072.

PMID:
21935173
25.

Hybrid plasmon/dielectric waveguide for integrated silicon-on-insulator optical elements.

Flammer PD, Banks JM, Furtak TE, Durfee CG, Hollingsworth RE, Collins RT.

Opt Express. 2010 Sep 27;18(20):21013-23. doi: 10.1364/OE.18.021013.

PMID:
20940996
26.

Pro-cathepsin D interacts with the extracellular domain of the beta chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth.

Beaujouin M, Prébois C, Derocq D, Laurent-Matha V, Masson O, Pattingre S, Coopman P, Bettache N, Grossfield J, Hollingsworth RE, Zhang H, Yao Z, Hyman BT, van der Geer P, Smith GK, Liaudet-Coopman E.

J Cell Sci. 2010 Oct 1;123(Pt 19):3336-46. doi: 10.1242/jcs.070938. Epub 2010 Sep 7.

27.

The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?

Muniz-Medina VM, Jones S, Maglich JM, Galardi C, Hollingsworth RE, Kazmierski WM, Ferris RG, Edelstein MP, Chiswell KE, Kenakin TP.

Mol Pharmacol. 2009 Mar;75(3):490-501. doi: 10.1124/mol.108.052555. Epub 2008 Dec 8.

PMID:
19064629
28.

Interference and resonant cavity effects explain enhanced transmission through subwavelength apertures in thin metal films.

Flammer PD, Schick IC, Collins RT, Hollingsworth RE.

Opt Express. 2007 Jun 25;15(13):7984-93.

PMID:
19547126
29.

CD44 modulates Smad1 activation in the BMP-7 signaling pathway.

Peterson RS, Andhare RA, Rousche KT, Knudson W, Wang W, Grossfield JB, Thomas RO, Hollingsworth RE, Knudson CB.

J Cell Biol. 2004 Sep 27;166(7):1081-91.

30.

Genotoxic stress-induced activation of Plk3 is partly mediated by Chk2.

Xie S, Wu H, Wang Q, Kunicki J, Thomas RO, Hollingsworth RE, Cogswell J, Dai W.

Cell Cycle. 2002 Nov-Dec;1(6):424-9.

PMID:
12548019
31.

Apoptotic regulation by the Crk adapter protein mediated by interactions with Wee1 and Crm1/exportin.

Smith JJ, Richardson DA, Kopf J, Yoshida M, Hollingsworth RE, Kornbluth S.

Mol Cell Biol. 2002 Mar;22(5):1412-23.

32.

PTCH2, a novel human patched gene, undergoing alternative splicing and up-regulated in basal cell carcinomas.

Zaphiropoulos PG, Undén AB, Rahnama F, Hollingsworth RE, Toftgård R.

Cancer Res. 1999 Feb 15;59(4):787-92.

33.

A human homolog of the yeast CDC7 gene is overexpressed in some tumors and transformed cell lines.

Hess GF, Drong RF, Weiland KL, Slightom JL, Sclafani RA, Hollingsworth RE.

Gene. 1998 Apr 28;211(1):133-40.

PMID:
9573348
34.

A retinoblastoma-binding protein related to a negative regulator of Ras in yeast.

Qian YW, Wang YC, Hollingsworth RE Jr, Jones D, Ling N, Lee EY.

Nature. 1993 Aug 12;364(6438):648-52.

PMID:
8350924
35.

Yeast pre-meiotic DNA replication utilizes mitotic origin ARS1 independently of CDC7 function.

Hollingsworth RE Jr, Sclafani RA.

Chromosoma. 1993 Jun;102(6):415-20.

PMID:
8365350
36.

Integration of cell cycle control with transcriptional regulation by the retinoblastoma protein.

Hollingsworth RE Jr, Chen PL, Lee WH.

Curr Opin Cell Biol. 1993 Apr;5(2):194-200. Review.

PMID:
8507491
37.

Retinoblastoma protein and the cell cycle.

Hollingsworth RE Jr, Hensey CE, Lee WH.

Curr Opin Genet Dev. 1993 Feb;3(1):55-62. Review.

PMID:
8453276
38.

Molecular genetic studies of the Cdc7 protein kinase and induced mutagenesis in yeast.

Hollingsworth RE Jr, Ostroff RM, Klein MB, Niswander LA, Sclafani RA.

Genetics. 1992 Sep;132(1):53-62.

39.

Tumor suppressor genes: new prospects for cancer research.

Hollingsworth RE, Lee WH.

J Natl Cancer Inst. 1991 Jan 16;83(2):91-6. Review.

PMID:
1988694
40.

RB protein as a cellular "corral" for growth-promoting proteins.

Lee WH, Hollingsworth RE Jr, Qian YW, Chen PL, Hong F, Lee EY.

Cold Spring Harb Symp Quant Biol. 1991;56:211-7. No abstract available.

PMID:
1819487
41.

DNA metabolism gene CDC7 from yeast encodes a serine (threonine) protein kinase.

Hollingsworth RE Jr, Sclafani RA.

Proc Natl Acad Sci U S A. 1990 Aug;87(16):6272-6.

Supplemental Content

Loading ...
Support Center